A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance – The ETOP 15-19 ABC-lung trial
- 21 February 2025
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 202, 108454
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche
This publication has 40 references indexed in Scilit:
- Chemotherapy and programmed cell death protein 1/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysisESMO Open, 2024
- Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR VariantJAMA, 2024
- Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyAnnals of Oncology, 2023
- 1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)Annals of Oncology, 2023
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at ProgressionClinical Lung Cancer, 2021
- Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategiesCancer Treatment Reviews, 2018
- Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30European Journal of Cancer, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trialsEuropean Journal of Cancer, 1994